RADNOR, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that members of senior management will be participating in fireside chats at three upcoming investor conferences.
| Guggenheim Healthcare Innovation Conference | |
| Date: | Tuesday, November 11, 2025 |
| Time: | 9:30am ET |
| Format: | Fireside Chat |
| Webcast Link | |
| Stifel Healthcare Conference | |
| Date: | Thursday, November 13, 2025 |
| Time: | 2:00pm ET |
| Format: | Fireside Chat |
| Webcast Link | |
| 8th Annual Evercore Healthcare Conference | |
| Date: | Wednesday December 3, 2025 |
| Time: | 3:25pm ET |
| Format: | Fireside Chat |
| Webcast Link | |
The live webcasts and archives of these fireside chats can also be accessed on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky.
Contact:
Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Relations
Melyssa Weible
Elixir Health Public Relations
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$38.02 |
| Daily Change: | 1.01 2.73 |
| Daily Volume: | 799,861 |
| Market Cap: | US$2.950B |
November 07, 2025 September 30, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
